Reuters: Global Markets: Peregrine Pharma shares fall on capital woes

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Peregrine Pharma shares fall on capital woes Sep 26th 2012, 22:50 Wed Sep 26, 2012 6:50pm EDT (Reuters) - Peregrine Pharmaceuticals Inc (PPHM.O) said it has capital to fund its operations until April as it was forced to pay off a loan after it reported errors in data from a lung cancer study, sending its shares down as much as 15 percent in extended trade. Its lenders deemed the company in default after Peregrine said on Monday that positive results reported earlier this month from the study contained major discrepancies, shocking investors and driving its shares down. In a regulatory filing, Peregrine said its lenders demanded payment of the outstanding principal amount of $15 million and accrued interest under a loan agreement dated August 30, 2012. Peregrine said it repaid the loan in full and its funds would last through the fourth quarter of its fiscal year 2013, unless it raises additional capital. Peregrine's shares closed at $1.66 on Wednesday on the Nasdaq, but fell to $1.41 after the bell.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions